1. New criteria for evaluating the efficacy of solid tumors: RECIST (Response Evaluation Criteria in Solid Tumors) Complete remission (CR, complete response) disappearance of all target lesions, no new lesions, and normal tumor markers, maintained for at least 4 weeks. Partial remission (PR, partial response) ≥ 30% reduction in the sum of the largest diameter of the target lesions, maintained for at least 4 weeks. SD (stable disease) The sum of the maximum diameter of the target lesions has not decreased to PR, or increased to PD. PD (progressive disease) The sum of the maximum diameter of the target lesions has increased by at least ≥20%, or new lesions have appeared. Note: If the longest diameter of only one target lesion increases by ≥20%, but the sum of the longest diameter of all recorded target lesions does not increase by 20%, it should not be evaluated as “PD”. 2. Commonly used indicators: Overall survival (OS, overall survival) The time from the start of randomization to death due to any cause. Duration of overall response: The time from the first appearance of CR or PR to the first diagnosis of PD or relapse. Duration of stable disease (DSD) is the time from the start of treatment to the time when the disease is evaluated as progressive. Disease-free survival (DFS) or disease-free survival time is the time from the start of randomization to the first relapse or death. Progression-free survival (PFS, progression-free survival) is the time between the start of enrollment and the time of tumor progression or death. Time to disease progression (TTP, Time to Progression) is the time from the start of randomization to the appearance of disease progression or death. Time to Treatment Failure (TTF, time to failure) is the time from the start of randomization to treatment discontinuation/termination, including any reasons for discontinuation/termination. Disease control rate (DCR, disease control rate): CR+PR+SD. Objective Response Rate (ORR, Objective Response Rate) The proportion of patients whose tumor shrinks by a certain amount and remains for a certain period of time, including cases of CR+PR. ORR (overall response rate) The proportion of treated CR+PR patients to the total number of evaluable cases. Remission rate (RR, response rate) The percentage of patients who achieved CR, PR to the total number of patients in the same period. Clinical benefit rate (CBR, clinical benefit rate): CR+PR+SD.